Table 3.
Ongoing Trials in BCMA
| Identifier | Title | Status | Interventions | Phase | Enrollment | Estimated Completion |
|---|---|---|---|---|---|---|
| ANTIBODY DRUG CONJUGATE (ADC) | ||||||
| NCT03828292 | An Open-label, Dose Escalation Study in Japanese Participants with Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments | Active, not recruiting | Drug: Belantamab mafodotin | Drug: Bortezomib | Drug: Dexamethasone | Drug: Pomalidomide | Phase 1 | 15 | 2023 |
| NCT04549363 | Characterization of Corneal Epithelial Changes in Participants Treated with Belantamab Mafodotin | Recruiting | Drug: Belantamab mafodotin | Phase 3 | 25 | 2023 |
| NCT04822337 | Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma | Recruiting | Drug: Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin | Phase 1 | Phase 2 | 70 | 2024 |
| NCT05208307 | Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma | Recruiting | Biological: Belantamab Mafodotin | Drug: Dexamethasone | Drug: Pomalidomide | Phase 2 | 34 | 2024 |
| NCT04036461 | A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants with Relapsed and Refractory Multiple Myeloma | Recruiting | Drug: CC-99712 | Drug: BMS-986405 | Phase 1 | 160 | 2025 |
| NCT04398745 | A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants with Normal and Varying Degree of Impaired Renal Function | Recruiting | Drug: Belantamab mafodotin | Phase 1 | 36 | 2025 |
| NCT04876248 | Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients with Minimal Residual Disease Positive After Stem Cell Transplant | Recruiting | Biological: Belantamab Mafodotin | Drug: Lenalidomide | Phase 2 | 20 | 2025 |
| NCT04680468 | Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma | Recruiting | Drug: Belantamab mafodotin | Phase 2 | 47 | 2026 |
| NCT04246047 | Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants with Relapsed/Refractory Multiple Myeloma | Active, not recruiting | Drug: Belantamab mafodotin | Drug: Daratumumab | Drug: Bortezomib | Drug: Dexamethasone | Phase 3 | 575 | 2026 |
| NCT04484623 | Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma | Recruiting | Drug: Belantamab mafodotin | Drug: Pomalidomide | Drug: Dexamethasone | Drug: Bortezomib | Phase 3 | 300 | 2027 |
| NCT04126200 | Platform Study of Belantamab Mafodotin as Monotherapy and in Combination with Anti-cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5) | Recruiting | Drug: Belantamab mafodotin | Drug: GSK3174998 | Drug: Feladilimab | Drug: Nirogacestat | Drug: Dostarlimab | Drug: Isatuximab | Drug: Lenalidomide | Drug: Dexamethasone | Drug: Pomalidomide | Phase 1 | Phase 2 | 464 | 2028 |
| NCT05117008 | Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma | Recruiting | Drug: Belantamab mafodotin | Phase 2 | 45 | 2032 |
| BISPECIFIC ANTIBODIES | ||||||
| NCT03269136 | PF-06863135 As Single Agent And In Combination with Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma | Active, not recruiting | Drug: PF-06863135 monotherapy IV or SC | Drug: PF-06863135 + dexamethasone | Drug: PF-06863135 + lenalidomide | Drug: PF-06863135 + pomalidomide | Phase 1 | 103 | 2023 |
| NCT04798586 | MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants with Multiple Myeloma | Active, not recruiting | Drug: Elranatamab (PF-06863135) | Phase 1 | 4 | 2023 |
| NCT04083534 | First In Human (FIH) Study of REGN5459 in Adult Patients with Relapsed or Refractory Multiple Myeloma (MM) | Active, not recruiting | Drug: REGN5459 | Phase 1 | Phase 2 | 43 | 2023 |
| NCT04649359 | MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants with Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb | Active, not recruiting | Drug: Elranatamab (PF-06863135) | Phase 2 | 187 | 2024 |
| NCT03145181 | Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma | Recruiting | Drug: Teclistamab (IV) | Drug: Teclistamab (SC) | Phase 1 | 282 | 2025 |
| NCT05228470 | A Study of Elranatamab (PF-06863135) in Chinese Participants with Refractory Multiple Myeloma. | Recruiting | Drug: Elranatamab | Phase 2 | 36 | 2025 |
| NCT05020236 | MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants with Relapsed/Refractory Multiple Myeloma | Recruiting | Drug: Elranatamab | Drug: Daratumumab | Drug: Pomalidomide | Drug: Dexamethasone | Phase 3 | 589 | 2025 |
| NCT04696809 | A Study of Teclistamab in Japanese Participants with Relapsed or Refractory Multiple Myeloma | Recruiting | Drug: Teclistamab | Phase 1 | Phase 2 | 38 | 2025 |
| NCT04557098 | A Study of Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma | Recruiting | Drug: Teclistamab | Phase 2 | 244 | 2025 |
| NCT04735575 | A Ph1/2 Study of EMB-06 in Participants with Relapsed or Refractory Myeloma | Recruiting | Biological: EMB-06 | Phase 1 | Phase 2 | 66 | 2025 |
| NCT03582033 | A Safety Study of SEA-BCMA in Patients with Multiple Myeloma | Active, not recruiting | Drug: SEA-BCMA | Drug: dexamethasone | Drug: pomalidomide | Phase 1 | 83 | 2026 |
| NCT05090566 | MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination with Anti-Cancer Treatments in Multiple Myeloma | Recruiting | Drug: Elranatamab + Nirogacestat | Drug: Elranatamab + lenalidomide + dexamethasone | Phase 2 | 105 | 2026 |
| NCT03933735 | A Study of TNB-383B in Participants with Relapsed or Refractory Multiple Myeloma | Active, not recruiting | Drug: TNB-383B | Phase 1 | Phase 2 | 220 | 2026 |
| NCT05535244 | A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants with Relapsed/Refractory Multiple Myeloma | Recruiting | Drug: Cevostamab | Drug: Tocilizumab | Phase 1 | Phase 2 | 140 | 2026 |
| NCT05014412 | A Study to Learn About the Study Medicine (Elranatamab) Either Alone or in Combination with Dexamethasone in Participants with Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment | Recruiting | Drug: Elranatamab | Drug: Elranatamab+ dexamethasone | Phase 2 | 76 | 2026 |
| NCT05675449 | A Clinical Trial of Three Medicines (Elranatamab Plus Carfilzomib and Dexamethasone) in People with Relapsed Refractory Multiple Myeloma | Recruiting | Drug: Elranatamab | Drug: Carfilzomib | Phase 1 | 14 | 2026 |
| NCT03486067 | Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants with Relapsed and Refractory Multiple Myeloma | Active, not recruiting | Drug: CC-93269 | Phase 1 | 220 | 2027 |
| NCT05623020 | A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, and Lenalidomide Compared with Daratumumab, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant | Recruiting | Drug: Elranatamab | Drug: Daratumumab | Drug: Lenalidomide | Drug: Dexamethasone | Phase 3 | 676 | 2028 |
| NCT05317416 | Study with Elranatamab Versus Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma After Transplant | Recruiting | Drug: Elranatamab | Drug: Lenalidomide | Phase 3 | 700 | 2029 |
| NCT05137054 | Linvolseltamab (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Participants with Relapsed/Refractory Multiple Myeloma (LINKER-MM2) | Recruiting | Drug: REGN5458 | Drug: Daratumumab | Drug: Carfilzomib | Drug: Lenalidomide | Drug: Bortezomib | Drug: Pomalidomide | Drug: Isatuximab | Drug: Nirogacestat | Phase 1 | 245 | 2032 |
| NCT03761108 | Phase 1/2 Study of REGN5458 in Patients with Relapsed or Refractory Multiple Myeloma | Active, not recruiting | Drug: REGN5458 | Phase 1 | Phase 2 | 309 | 2032 |
| CAR T/NK cells | ||||||
| NCT04162353 | BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma | Recruiting | Biological: BCMA-CD19 cCAR T cells | Phase 1 | 12 | 2021 |
| NCT03943472 | BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma | Recruiting | Biological: Anti-BCMA CAR-T cells | Drug: Fludarabine | Drug: Cyclophosphamide | Drug: Immune inhibitors | Early Phase 1 | 10 | 2022 |
| NCT04236011 | BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma | Recruiting | Biological: GC012F injection | Early Phase 1 | 15 | 2022 |
| NCT05346198 | Evaluate CART-BCMA in Patients with Relapsed and/or Refractory Multiple Myeloma | Recruiting | Drug: CART-BCMA | Phase 1 | 15 | 2023 |
| NCT04637269 | Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma | Recruiting | Biological: anti-BCMA CAR-T | Early Phase 1 | 16 | 2023 |
| NCT04271644 | BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma | Recruiting | Biological: BCMA CAR-T cells | Phase 1 | Phase 2 | 80 | 2023 |
| NCT04272151 | Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma | Recruiting | Biological: BCMA CAR-T cells | Phase 1 | Phase 2 | 40 | 2023 |
| NCT04776330 | A Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma | Recruiting | Biological: BCMA targeted prime CAR-T cells | Phase 1 | Phase 2 | 80 | 2023 |
| NCT03380039 | Clinical Study of CAR-BCMA T Cells in Patients with Refractory or Relapsed Multiple Myeloma | Active, not recruiting | Genetic: CAR-BCMA T cells | Drug: Fludarabine | Drug: Cyclophosphamide | Not Applicable | 6 | 2023 |
| NCT05008536 | Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma | Recruiting | Biological: Anti-BCMA CAR-NK Cells | Drug: Fludarabine | Drug: Cytoxan | Early Phase 1 | 27 | 2023 |
| NCT03716856 | Clinical Study of CAR-BCMA T in Patients with Refractory or Relapsed Multiple Myeloma | Active, not recruiting | Genetic: CAR-BCMA T cells | Drug: Fludarabine | Drug: Cyclophosphamide | Phase 1 | 11 | 2023 |
| NCT04662099 | T Cells Expressing a Bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple Myeloma | Recruiting | Biological: Conditioning chemotherapy followed by CAR T cell infusion | Phase 1 | 24 | 2023 |
| NCT04714827 | Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients with Relapsed or Refractory Multiple Myeloma | Recruiting | Biological: CD19-CD22 CAR-T cells | Phase 1 | Phase 2 | 24 | 2023 |
| NCT05201118 | A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined with Selinexor in Patients with Relapsed/Refractory Extramedullary Multiple Myeloma | Recruiting | Drug: Selinexor | Drug: CT103A | Phase 1 | 20 | 2023 |
| NCT05652530 | Clinical Study of the Safety and Efficacy of BCMA CAR-NK | Recruiting | Drug: Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK) | Early Phase 1 | 19 | 2023 |
| NCT03455972 | Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed with Auto-HSCT | Recruiting | Biological: anti-CD19 and anti-BCMA CAR | Drug: Immunomodulatory drugs | Phase 1 | Phase 2 | 15 | 2023 |
| NCT03430011 | Study Evaluating the Safety and Efficacy of JCARH125 in Subjects with Relapsed and/or Refractory Multiple Myeloma | Active, not recruiting | Biological: JCARH125 | Biological: JCARH125 + anakinra | Phase 1 | Phase 2 | 169 | 2023 |
| NCT05336383 | Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma | Recruiting | Drug: Radiation Therapy | Phase 2 | 30 | 2023 |
| NCT04935580 | Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients | Recruiting | Biological: GC012F injection | Phase 1 | Phase 2 | 20 | 2023 |
| NCT03302403 | Clinical Study of Redirected Autologous T Cells with a Chimeric Antigen Receptor in Patients with Malignant Tumors | Active, not recruiting | Genetic: CAR-CD19 T cell | Genetic: CAR-BCMA T cell | Genetic: CAR-GPC3 T cell | Genetic: CAR-CLD18 T cell | Drug: Fludarabine | Drug: Cyclophosphamide | Not Applicable | 18 | 2023 |
| NCT04196491 | A Study to Evaluate the Safety of bb2121 in Subjects with High Risk, Newly Diagnosed Multiple Myeloma (NDMM) | Active, not recruiting | Biological: bb2121 | Drug: Fludarabine | Drug: Cyclophosphamide | Drug: Lenalidomide | Phase 1 | 13 | 2023 |
| NCT04003168 | Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma | Recruiting | Drug: Human BCMA targeted T Cells Injection | Phase 1 | 18 | 2024 |
| NCT05712083 | A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma | Recruiting | Drug: BCMA CAR-T cells | Phase 2 | 40 | 2024 |
| NCT03602612 | T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma | Active, not recruiting | Drug: Cyclophosphamide | Drug: Fludarabine | Biological: Anti-BCMA CAR T cells | Phase 1 | 35 | 2024 |
| NCT04706936 | Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma | Recruiting | Biological: anti-BCMA CAR-T | Drug: Cyclophosphamide | Drug: Fludarabine | Phase 1 | 25 | 2024 |
| NCT03070327 | BCMA Targeted CAR T Cells with or without Lenalidomide for the Treatment of Multiple Myeloma | Active, not recruiting | Biological: EGFRt/BCMA-41BBz CAR T cell | Drug: Cyclophosphamide | Drug: Lenalidomide. | Phase 1 | 20 | 2024 |
| NCT05302648 | To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM | Recruiting | Drug: Human Derived anti-BCMA CAR-T Injection | Early Phase 1 | 18 | 2024 |
| NCT05066646 | A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma (FUMANBA-1) | Recruiting | Drug: CT103A | Phase 1 | Phase 2 | 132 | 2024 |
| NCT05150522 | B Cell Maturation Antigen Targeted CAR-T Cells in Treatment with Relapsed and Refractory Multiple Myeloma | Recruiting | Biological: BCMA CAR-T cells | Phase 1 | Phase 2 | 10 | 2024 |
| NCT04601935 | A Single-center Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a BCMA-targeted Universal LCAR-BCX Cells in Patients with Relapsed/Refractory Multiple Myeloma | Active, not recruiting | Biological: LCAR-BCX cells product | Phase 1 | 34 | 2024 |
| NCT05412329 | Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma | Recruiting | Biological: GC012F injection | Phase 1 | 9 | 2024 |
| NCT03994705 | Descartes-11 in Multiple Myeloma | Active, not recruiting | Biological: Descartes-11 | Drug: Fludarabine | Drug: Cyclophosphamide | Phase 1 | Phase 2 | 25 | 2024 |
| NCT03361748 | Efficacy and Safety Study of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma | Active, not recruiting | Biological: bb2121 | Phase 2 | 149 | 2024 |
| NCT05618041 | The Safety and Efficacy Investigation of CAR-T Cell Therapy for Patients with Hematological Malignancies | Recruiting | Biological: CAR-T Autologous T cell injection | Not Applicable | 50 | 2024 |
| NCT04677452 | Dose Exploration Study OF JWCAR129, BCMA-Targeted CART for RRMM | Recruiting | Biological: JWCAR129 | Phase 1 | 24 | 2024 |
| NCT05266768 | Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002# | Recruiting | Drug: IBI346 | Phase 1 | 36 | 2024 |
| NCT05270928 | Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001# | Recruiting | Drug: IBI346 | Phase 1 | 42 | 2024 |
| NCT05430945 | A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma | Recruiting | Biological: BCMA Targeted CAR T-cells | Early Phase 1 | 100 | 2025 |
| NCT05509530 | Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (rr/MM) | Recruiting | Other: anti-BCMA/GPRC5D CAR-T CELL | Phase 2 | 30 | 2025 |
| NCT03975907 | Clinical Trial to Evaluate CT053 in Patients with Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1) | Recruiting | Biological: CAR-BCMA T Cells | Phase 1 | Phase 2 | 114 | 2025 |
| NCT04318327 | BCMA-directed CAR-T Cell Therapy in Adult Patients with Relapsed and/or Refractory Multiple Myeloma | Recruiting | Biological: PHE885 | Phase 1 | 56 | 2025 |
| NCT04287660 | Study of BiRd Regimen Combined with BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients | Recruiting | Drug: clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells | Phase 3 | 20 | 2025 |
| NCT04309981 | Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients with Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody. | Recruiting | Biological: Adult differentiated autologous T-cells with anti-BCMA specificity | Phase 1 | Phase 2 | 36 | 2025 |
| NCT04133636 | A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants with Multiple Myeloma | Recruiting | Drug: JNJ-68284528 | Drug: Lenalidomide | Drug: Daratumumab | Drug: Bortezomib | Drug: Dexamethasone | Phase 2 | 157 | 2025 |
| NCT04394650 | A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants with Relapsed and/or Refractory Multiple Myeloma | Active, not recruiting | Biological: CC-98633 | Phase 1 | 150 | 2025 |
| NCT05740891 | AHSCT Combined with CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma | Recruiting | Drug: BCMA CAR-T cells injection | Phase 1 | 50 | 2025 |
| NCT05032820 | MM CAR-T to Upgrade Response BMTCTN1902 | Recruiting | Drug: Lenalidomide and bb2121 | Phase 2 | 40 | 2025 |
| NCT05632380 | ASCT in Combination with C-CAR088 for Treating Patients with Ultra High-risk Multiple Myeloma (MM) | Recruiting | Procedure: Autologous hematopoietic stem cell transplantation | Biological: C-CAR088 | Phase 1 | Phase 2 | 20 | 2025 |
| NCT05172596 | PHE885 CAR-T Therapy in Adult Participants with Relapsed and Refractory Multiple Myeloma | Recruiting | Biological: PHE885 | Phase 2 | 136 | 2025 |
| NCT03274219 | Study of bb21217 in Multiple Myeloma | Active, not recruiting | Biological: bb21217 | Phase 1 | 72 | 2025 |
| NCT05396885 | Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma (iMMagine-1) | Recruiting | Biological: CART-ddBCMA | Phase 2 | 110 | 2025 |
| NCT03196414 | Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma | Recruiting | Biological: CART-138/BCMA/19/more | Phase 1 | Phase 2 | 10 | 2026 |
| NCT03758417 | A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants with Relapsed or Refractory Multiple Myeloma | Recruiting | Biological: LCAR-B38M CAR-T Cell | Phase 2 | 130 | 2026 |
| NCT05376345 | BCMA-targeted LCAR-BCDR Cells in Patients with Relapsed/Refractory Multiple Myeloma | Recruiting | Biological: LCAR-BCDR cells product | Phase 1 | 32 | 2026 |
| NCT04720313 | NXC-201 (Formerly HBI0101) Multiple Myeloma | Recruiting | Drug: NXC-201 (formerly HBI0101) | Phase 1 | 48 | 2026 |
| NCT04603872 | CAR-T Cells Combined with Dasatinib for Patients with Relapsed and/or Refractory B-cell Hematological Malignancies | Recruiting | Drug: CD19/BCMA Targeted CAR T-cells and dasatinib | Drug: CD19/BCMA Targeted CAR T-cells | Early Phase 1 | 120 | 2026 |
| NCT05528887 | Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies | Recruiting | Biological: Autologous CAR-T cells | Drug: Fludarabine | Drug: Cyclophosphamide | Phase 1 | 10 | 2026 |
| NCT05594797 | Human BCMA Targeted T Cells Injection (BCMA CAR-T) for Subjects with R/R MM | Recruiting | Drug: Human BCMA Targeted T Cells Injection | Phase 2 | 100 | 2027 |
| NCT05722418 | CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma | Recruiting | Biological: CB-011 | Phase 1 | 50 | 2027 |
| NCT04093596 | Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults with Relapsed or Refractory Multiple Myeloma (UNIVERSAL) | Recruiting | Genetic: ALLO-715 | Biological: ALLO-647 | Drug: Fludarabine | Drug: Cyclophosphamide | Drug: Nirogacestat | Phase 1 | 132 | 2027 |
| NCT05000450 | Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma | Recruiting | Genetic: ALLO-605 | Biological: ALLO-647 | Drug: Fludarabine | Drug: Cyclophosphamide | Phase 1 | Phase 2 | 136 | 2027 |
| NCT04181827 | A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants with Relapsed and Lenalidomide-Refractory Multiple Myeloma | Active, not recruiting | Drug: JNJ-68284528 | Drug: Pomalidomide | Drug: Bortezomib | Drug: Dexamethasone | Drug: Daratumumab | Phase 3 | 419 | 2027 |
| NCT04244656 | A Safety and Efficacy Study Evaluating CTX120 in Subjects with Relapsed or Refractory Multiple Myeloma | Active, not recruiting | Biological: CTX120 | Phase 1 | 26 | 2027 |
| NCT05243212 | Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma | Recruiting | Biological: CAR-BCMA | Phase 1 | Phase 2 | 75 | 2028 |
| NCT03601078 | An Efficacy and Safety Study of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects with High-Risk Multiple Myeloma | Recruiting | Biological: bb2121 | Drug: Lenalidomide | Phase 2 | 235 | 2030 |
| NCT03741127 | Long-Term Follow-Up Study for Subjects Treated with P-BCMA-101 | Active, not recruiting | Drug: Rimiducid may be administered as indicated | Phase 1 | 100 | 2032 |
| NCT03915184 | Clinical Trial to Evaluate Zevor-cel (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2) | Recruiting | Biological: zevor-cel | Phase 1 | Phase 2 | 105 | 2034 |
| NCT04923893 | A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy | Recruiting | Drug: Bortezomib | Drug: Dexamethasone | Drug: Lenalidomide | Drug: Cilta-cel | Drug: Cyclophosphamide | Drug: Fludarabine | Phase 3 | 650 | 2034 |
| NCT04155749 | Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma | Recruiting | Drug: CART-ddBCMA | Drug: ARC-T Plus Anti-BCMA SparX | Phase 1 | 65 | 2035 |
| NCT03549442 | Up-front CART-BCMA with or without huCART19 in High-risk Multiple Myeloma | Active, not recruiting | Combination Product: BCMA CART + huCART19 | Combination Product: CART BCMA or CART BCMA + huCART19 | Combination Product: Single-dose infusion of CART BCMA or CART BCMA + huCART19 | Phase 1 | 40 | 2036 |
| NCT04613557 | Safety, Activity and Cell Kinetics of CYAD-211 in Patients with Relapsed or Refractory Multiple Myeloma | Recruiting | Biological: CYAD-211 | Drug: Endoxan | Drug: Fludara | Phase 1 | 12 | 2036 |
| NCT05521802 | A Study of C-CAR088 in Patients with Relapsed or Refractory Multiple Myeloma | Recruiting | Biological: B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR)-T cell | Phase 1 | Phase 2 | 92 | 2037 |
| NCT05577000 | Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma | Recruiting | Biological: Manufactured Anti-BCMA CAR-T cells | Drug: Fludarabine | Drug: Cyclophosphamide | Phase 1 | 24 | 2039 |
| NCT04960579 | P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects with Multiple Myeloma | Recruiting | Biological: P-BCMA-ALLO1 CAR-T cells | Drug: Rimiducid | Phase 1 | 135 | 2040 |
| NCT05182073 | FT576 in Subjects with Multiple Myeloma | Recruiting | Drug: FT576 (Allogenic CAR NK cells with BCMA expression) | Drug: Cyclophosphamide | Drug: Fludarabine | Drug: Daratumumab | Phase 1 | 168 | 2040 |